

## Research Space

Journal article

**Planned delivery to improve postpartum cardiac function in women with preterm pre-eclampsia: the PHOEBE mechanisms of action study within the PHOENIX RCT**

**McCarthy, F, O'Driscoll, J., Seed, P, Brockbank, A, Cox, A, Gill, C, Green, M, Marber, M, Poston, L, Placzek, A, Shennan, A.H, Sparkes, J, Leeson, P, Thilaganathan, B and Chappell, L.C**

McCarthy FP, O'Driscoll J, Seed P, Brockbank A, Cox A, Gill C, et al. Planned delivery to improve postpartum cardiac function in women with preterm pre-eclampsia: the PHOEBE mechanisms of action study within the PHOENIX RCT. *Efficacy Mech Eval* 2021;8(12).

## Efficacy and Mechanism Evaluation

Volume 8 • Issue 12 • September 2021

ISSN 2050-4365

# Planned delivery to improve postpartum cardiac function in women with preterm pre-eclampsia: the PHOEBE mechanisms of action study within the PHOENIX RCT

*Fergus P McCarthy, Jamie O'Driscoll, Paul Seed, Anna Brockbank, Alice Cox, Carolyn Gill, Marcus Green, Mike Marber, Lucilla Poston, Anna Placzek, Andrew Shennan, Jenie Sparkes, Paul Leeson, Basky Thilaganathan and Lucy C Chappell*





# Planned delivery to improve postpartum cardiac function in women with preterm pre-eclampsia: the PHOEBE mechanisms of action study within the PHOENIX RCT

Fergus P McCarthy<sup>ID,1,2\*</sup> Jamie O'Driscoll<sup>ID,3,4</sup> Paul Seed<sup>ID,1</sup>  
Anna Brockbank<sup>ID,1</sup> Alice Cox<sup>ID,5</sup> Carolyn Gill<sup>ID,1</sup>  
Marcus Green<sup>ID,6</sup> Mike Marber<sup>ID,7</sup> Lucilla Poston<sup>ID,1</sup>  
Anna Placzek<sup>ID,8</sup> Andrew Shennan<sup>ID,1</sup> Jenie Sparkes<sup>ID,1</sup>  
Paul Leeson<sup>ID,9†</sup> Basky Thilaganathan<sup>ID,10†</sup>  
and Lucy C Chappell<sup>ID,1\*†</sup>

<sup>1</sup>Department of Women and Children's Health, King's College London, London, UK

<sup>2</sup>Department of Obstetrics and Gynaecology, The INFANT Research Centre, University College Cork, Cork University Maternity Hospital, Cork, Ireland

<sup>3</sup>School of Human and Life Science, Canterbury Christ Church University, Kent, UK

<sup>4</sup>Department of Cardiology, St George's University Hospitals NHS Foundation Trust, London, UK

<sup>5</sup>Women's Services, University College London, London, UK

<sup>6</sup>Action on Pre-eclampsia, Evesham, UK

<sup>7</sup>Cardiovascular Division, King's College London British Heart Foundation Centre of Excellence, The Rayne Institute, St. Thomas' Hospital Campus, London, UK

<sup>8</sup>National Perinatal Epidemiology Unit (NPEU), Nuffield Department of Population Health, University of Oxford, Oxford, UK

<sup>9</sup>Oxford Cardiovascular Clinical Research Facility, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

<sup>10</sup>Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust and Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK

\*Corresponding authors

†These authors contributed equally

**Declared competing interests of authors:** Lucy C Chappell is the chairperson of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Clinical Evaluation and Trials Committee (January 2019 to present). Lucy C Chappell is funded by the NIHR Professorship, RP-2014-05-019, and has also been awarded the following NIHR funding: 12/164/16, 15/59/06, NIHR128721 and RP-2014-05-01. Lucy C Chappell declares that following the completion of this research project, she took up the role of Chief Scientific Adviser for the Department of Health and Social Care from 1 August 2021. Andrew Shennan is a member of the NIHR HTA Commissioning Committee. Mike Marber is named as an inventor on a patent (WO 2010/130985 A1) held by King's College London for the detection of cardiac myosin-binding protein C (cMyC) as a biomarker of myocardial injury.



Published September 2021

DOI: 10.3310/eme08120

This report should be referenced as follows:

McCarthy FP, O'Driscoll J, Seed P, Brockbank A, Cox A, Gill C, *et al.* Planned delivery to improve postpartum cardiac function in women with preterm pre-eclampsia: the PHOEBE mechanisms of action study within the PHOENIX RCT. *Efficacy Mech Eval* 2021;**8**(12).



# Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)

ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full EME archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/eme](http://www.journalslibrary.nihr.ac.uk/eme). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Efficacy and Mechanism Evaluation* journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

## EME programme

The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

## This report

The research reported in this issue of the journal was funded by the EME programme as project number 15/23/02. The contractual start date was in April 2016. The final report began editorial review in November 2019 and was accepted for publication in September 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2021. This work was produced by McCarthy *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).



## NIHR Journals Library Editor-in-Chief

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

## NIHR Journals Library Editors

---

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont** Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Planned delivery to improve postpartum cardiac function in women with preterm pre-eclampsia: the PHOEBE mechanisms of action study within the PHOENIX RCT

Fergus P McCarthy<sup>1,2\*</sup> Jamie O'Driscoll<sup>3,4</sup> Paul Seed<sup>1</sup>  
Anna Brockbank<sup>1</sup> Alice Cox<sup>5</sup> Carolyn Gill<sup>1</sup> Marcus Green<sup>6</sup>  
Mike Marber<sup>7</sup> Lucilla Poston<sup>1</sup> Anna Placzek<sup>8</sup> Andrew Shennan<sup>1</sup>  
Jenie Sparkes<sup>1</sup> Paul Leeson<sup>9†</sup> Basky Thilaganathan<sup>10†</sup>  
and Lucy C Chappell<sup>1\*†</sup>

<sup>1</sup>Department of Women and Children's Health, King's College London, London, UK

<sup>2</sup>Department of Obstetrics and Gynaecology, The INFANT Research Centre, University College Cork, Cork University Maternity Hospital, Cork, Ireland

<sup>3</sup>School of Human and Life Science, Canterbury Christ Church University, Kent, UK

<sup>4</sup>Department of Cardiology, St George's University Hospitals NHS Foundation Trust, London, UK

<sup>5</sup>Women's Services, University College London, London, UK

<sup>6</sup>Action on Pre-eclampsia, Evesham, UK

<sup>7</sup>Cardiovascular Division, King's College London British Heart Foundation Centre of Excellence, The Rayne Institute, St. Thomas' Hospital Campus, London, UK

<sup>8</sup>National Perinatal Epidemiology Unit (NPEU), Nuffield Department of Population Health, University of Oxford, Oxford, UK

<sup>9</sup>Oxford Cardiovascular Clinical Research Facility, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

<sup>10</sup>Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust and Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK

\*Corresponding authors [Fergus.mccarthy@ucc.ie](mailto:Fergus.mccarthy@ucc.ie) and [lucy.chappell@kcl.ac.uk](mailto:lucy.chappell@kcl.ac.uk)

†These authors contributed equally

**Background:** Women whose pregnancies are affected by hypertensive disorders of pregnancy, in particular preterm pre-eclampsia, are at increased risk of long-term cardiovascular morbidity and mortality.

**Objectives:** To investigate the hypothesis that prolongation of a pregnancy affected by preterm pre-eclampsia managed by expectant management compared with planned early delivery would result in worse cardiovascular function 6 months postpartum.

**Design:** A randomised controlled trial.

**Setting:** 28 maternity hospitals in England and Wales.

**Participants:** Women who were eligible for the Pre-eclampsia in HOspital: Early iNductlon or eXpectant management (PHOENIX) study were approached and recruited for the PHOEBE study. The PHOENIX (Pre-eclampsia in HOspital: Early iNductlon or eXpectant management) study was a parallel-group, non-masked, multicentre, randomised controlled trial that was carried out in 46 maternity units across England and Wales. This study compared planned early delivery with expectant management (usual care) with individual randomisation in women with late preterm

pre-eclampsia who were 34 weeks' gestation to less than 37 weeks' gestation and having a singleton or dichorionic diamniotic twin pregnancy.

**Interventions:** Postpartum follow-up included medical history, blood pressure assessment and echocardiography. All women had blood sampling performed on at least two time points from recruitment to the 6-month follow-up for assessment of cardiac necrosis markers.

**Main outcome measures:** Primary outcome was a composite of systolic and/or diastolic dysfunction (originally by 2009 guidelines then updated by 2016 guidelines, with an amended definition of diastolic dysfunction). Analyses were by intention to treat, together with a per-protocol analysis for the primary and secondary outcomes.

**Results:** Between 27 April 2016 and 30 November 2018, 623 women were found to be eligible, of whom 420 (67%) were recruited across 28 maternity units in England and Wales. A total of 133 women were allocated to planned delivery, 137 women were allocated to expectant management and a further 150 received non-randomised expectant management within usual care. The mean time from enrolment to delivery was 2.5 (standard deviation 1.9) days in the planned delivery group compared with 6.8 (standard deviation 5.3) days in the expectant management group. There were no differences in the primary outcome between women in the planned delivery group and those in the expectant management group using either the 2009 (risk ratio 1.06, 95% confidence interval 0.80 to 1.40) or the 2016 definition (risk ratio 0.78, 95% confidence interval 0.33 to 1.86). Overall, 10% (31/321) of women had a left ventricular ejection fraction < 55% and 71% of the cohort remained hypertensive at 6 months postpartum. No differences were observed between groups in cardiorespiratory outcomes prior to discharge from hospital or in systolic or diastolic blood pressure measurements. Variables associated with the primary outcome (2009 definition) at 6 months postpartum were maternal body mass index (adjusted odds ratio 1.33 per 5 kg/m<sup>2</sup>, 95% confidence interval 1.12 to 1.59 per 5 kg/m<sup>2</sup>) and maternal age (adjusted odds ratio 2.16, 95% confidence interval 1.44 to 3.22 per 10 years). Limitations include changing definitions regarding systolic and/or diastolic dysfunction.

**Conclusions:** Preterm pre-eclampsia results in persistence of hypertension in the majority of women with late preterm pre-eclampsia at 6 months postpartum and systolic dysfunction in 10%. Pre-eclampsia should not be considered a self-limiting disease of pregnancy alone.

**Future work:** Interventions aimed at reducing cardiovascular dysfunction.

**Trial registration:** Current Controlled Trials ISRCTN01879376.

**Funding:** This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in *Efficacy and Mechanism Evaluation*; Vol. 8, No. 12. See the NIHR Journals Library website for further project information.

# Contents

List of tables	xi
List of figures	xiii
List of abbreviations	xv
Plain English summary	xvii
Scientific summary	xix
<b>Chapter 1</b> Introduction	<b>1</b>
<b>Chapter 2</b> Methods	<b>3</b>
Study design and participants	3
Randomisation and masking	3
Procedures	3
Outcomes	4
Echocardiographic assessment	4
Heart remodelling	4
Systolic and diastolic dysfunction	4
Myocardial necrosis assessment	5
Statistical analysis	5
<b>Chapter 3</b> Results	<b>7</b>
<b>Chapter 4</b> Discussion	<b>17</b>
<b>Acknowledgements</b>	<b>21</b>
<b>References</b>	<b>23</b>



## List of tables

<b>TABLE 1</b> Baseline maternal demographic and pregnancy characteristics at trial entry for all women who underwent 6-month echocardiography ( $n = 321$ )	<b>8</b>
<b>TABLE 2</b> Maternal clinical characteristics for women with primary outcome	<b>9</b>
<b>TABLE 3</b> Primary and secondary outcomes at 6 months postpartum	<b>10</b>
<b>TABLE 4</b> Secondary outcomes at discharge following delivery	<b>13</b>
<b>TABLE 5</b> Effect of baseline characteristics on the development of cardiovascular dysfunction (2009 definition) at 6 months postpartum (all women)	<b>14</b>
<b>TABLE 6</b> Effect of baseline characteristics on the development of systolic and/or diastolic dysfunction (2016 definition) at 6 months postpartum ( $n = 321$ )	<b>15</b>



# List of figures

FIGURE 1 Participant flow chart

7





## List of abbreviations

BMI	body mass index	OR	odds ratio
CI	confidence interval	PHOENIX	Pre-eclampsia in HOspital: Early iNduction or eXpectant management
cTnI	highly sensitive cardiac troponin-I	RR	risk ratio
FiO <sub>2</sub>	fraction of inspired oxygen	SD	standard deviation
HTA	Health Technology Assessment	SpO <sub>2</sub>	oxygen saturation
NIHR	National Institute for Health Research	TDI	tissue Doppler imaging



## Plain English summary

**W**omen who have a form of high blood pressure in pregnancy called pre-eclampsia may be at risk of heart disease later in life. When a woman becomes unwell with this type of high blood pressure in pregnancy we usually wait until she is 37 weeks pregnant before recommending delivery. We carried out a study to see if earlier delivery would lead to fewer complications for the woman and the baby, and to see if this would also reduce her risk of damage to her heart after pregnancy.

This study was part of a larger study called the Pre-eclampsia in HOspital: Early iNduction or eXpectant management (PHOENIX) study. In this study, women with pre-eclampsia between 34 and 37 weeks of pregnancy either had birth started within 48 hours (usually by induction of labour) or underwent usual care, waiting until the doctor thought that she needed delivery or she reached 37 weeks of pregnancy. In our study, we invited women back 6 months after having their baby, performed an ultrasound of their hearts and checked blood pressure. We then looked to see whether or not being delivered earlier caused less damage to the heart.

Between April 2016 and November 2018, 420 women in 28 hospitals in the England and Wales agreed to take part.

We showed that staying pregnant with pre-eclampsia for a few days longer did not cause more heart damage. However, 1 in 10 women in the study had ultrasound evidence of damage to their hearts. Over half of the women in the study did not have a normal ultrasound of their heart. Around 7 out of 10 of these women with pre-eclampsia still had high blood pressure 6 months after their pregnancy. These findings suggest that these women need more intensive monitoring and follow-up after their pregnancy. This might help reduce the long-term risks of heart disease.



# Scientific summary

## Background

Pre-eclampsia affects 3–5% of pregnancies, complicating approximately 35,000 pregnancies in the UK every year. Cardiovascular disease is the leading cause of mortality in women in the UK. Hypertensive disorders of pregnancy, in particular preterm pre-eclampsia, have been shown to be associated with an increased risk of development of a wide range of cardiovascular diseases, with increases in incidences observed as soon as 1 year postpartum. The absolute risk that a woman with pre-eclampsia would develop a cardiovascular event including hypertension, ischaemic heart disease, stroke or venous thromboembolism when she reaches the age of 50–59 years is estimated to be 17.8%, compared with 8.3% in those without pre-eclampsia.

The Pre-eclampsia in HOspital: Early iNductlon or eXpectant management (PHOENIX) study, a multicentre, randomised controlled trial, recruited women with late preterm pre-eclampsia who were 34 weeks' gestation to less than 37 weeks' gestation and having a singleton or dichorionic diamniotic twin pregnancy. It demonstrated that initiation of planned delivery in the subsequent 48 hours after randomisation reduced severe maternal adverse outcomes with no difference in neonatal morbidity (but there were more neonatal unit admissions) compared with the current practice of expectant management until 37 weeks' gestation. This PHOENIX study provided a key opportunity to examine the mechanisms underlying cardiovascular dysfunction following a randomised intervention on timing of delivery. An associated editorial alongside the main trial publication questioned whether initiating delivery in late preterm pre-eclampsia rather than waiting until term might theoretically reduce the stress on the woman's cardiovascular system (Staff AC. Long-term cardiovascular health after stopping pre-eclampsia. *Lancet* 2019;**394**:1120–1). The editorial advised evaluating whether or not a change to active delivery of women with late preterm pre-eclampsia would also benefit maternal cardiovascular health in the long term.

We conducted a follow-up cardiovascular assessment of women eligible for the PHOENIX study to examine the hypothesis that planned delivery in women with preterm pre-eclampsia, with attendant myocardial ischaemia, may decrease the risk of the development of cardiovascular dysfunction following pregnancy.

## Objectives

The main aim of this mechanistic study was to examine the effects of shortening pregnancy complicated by pre-eclampsia on cardiovascular function at 6 months postpartum by studying women enrolled in a randomised controlled trial of planned delivery compared with usual care (expectant management) and who had late preterm pre-eclampsia.

## Methods

### Study design and participants

In this parallel-group, non-masked, multicentre, randomised controlled trial, we compared cardiovascular function at 6 months postpartum in women with preterm pre-eclampsia who were managed by planned delivery against expectant management (usual care). This trial was carried out in 28 consultant-led maternity units in England and Wales. Participants who were eligible for the PHOENIX study were approached following their decision to participate. A pregnant woman was eligible if she was between

34<sup>+0</sup> and 36<sup>+6</sup> weeks' gestation, had a diagnosis of pre-eclampsia or superimposed pre-eclampsia [as defined by the International Society for the Study of Hypertension in Pregnancy (Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, *et al.* The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. *Pregnancy Hypertens* 2014;4:97–104)], with a singleton or dichorionic diamniotic twin pregnancy and at least one viable fetus, was aged  $\geq 18$  years, and was able to give written informed consent. The only exclusion criterion to study participation was if a decision had already been made to deliver her baby in the next 48 hours. There were no substantial changes to the published study design, methods or outcomes after the start of the trial. The trial was approved by the South Central – Hampshire B Research Ethics Committee (number 13/SC/0645).

### **Randomisation and masking**

Participants were randomly assigned to planned delivery or expectant care in a 1 : 1 ratio, as previously described. When women declined participation in the PHOENIX study, participation in the PHOEBE study was offered and these women were included as a third, non-randomised expectant (usual-care) group. The intervention was not masked from women, clinicians or data collectors because of the nature of the intervention. Trial statisticians were also not masked to allocation. However, the trial echocardiographer (JOD) was blinded to allocation group in analysis of all echocardiograms.

### **Procedures**

Women were approached about participating in the PHOENIX study. Regardless of their participation in the PHOENIX study, site research teams approached women to confirm their eligibility and to provide verbal and written information. A trained research midwife or clinician obtained written informed consent. A research team member entered baseline data on a web-based database. All other aspects of pregnancy management were expected to be in accordance with the UK national guidelines at the discretion of the responsible clinician. Outcomes were recorded on the web-based trial database through case note review by trained researchers after maternal primary hospital discharge. Women were invited to return to their local hospital at least 6 months following delivery for echocardiography assessment, which was performed within an 8-week window. At this assessment, a brief medical history was recorded, blood pressure was assessed, and venepuncture and echocardiography were undertaken. Echocardiography was performed locally in accordance with a standard operating procedure circulated by the research team. Anonymised echocardiography discs were then sent to the lead echocardiographer (JOD), who analysed each echocardiogram without knowledge of trial allocation and entered results into the web-based trial database. Every tenth echocardiogram was second read, again masked to trial allocation, by an echocardiographer at the University of Oxford and the findings were compared by the trial lead cardiologist (PL) to ensure consistency. When echocardiography assessment demonstrated potentially concerning features that may have an impact on clinical care, the findings were escalated and reviewed by the lead cardiologist (PL) and communicated back to the lead clinician at the recruiting site with a clinical recommendation for follow-up.

### **Outcomes**

The primary outcome was a composite of diastolic and systolic function at 6 months postpartum classified according to the joint recommendation by the American Society of Echocardiography and the European Association of Cardiovascular Imaging as assessed by transthoracic echocardiography with tissue Doppler studies, originally classified in 2009 and updated prior to study completion in 2016. Secondary outcomes included systolic blood pressure and diastolic blood pressure at 6 months postpartum, together with the cardiovascular components of the fullPIERS (Preeclampsia Integrated Estimate of RiSk) composite maternal morbidity outcome, which was adapted from the fullPIERS prediction of adverse events in pre-eclampsia study. The cardiovascular components from the maternal morbidity composite outcome in the PHOENIX study included severe hypertension post randomisation (systolic blood pressure  $\geq 160$  mmHg on at least one occasion), positive inotropic support, infusion of a third parenteral antihypertensive drug, myocardial ischaemia or infarction, oxygen saturation ( $\text{SpO}_2$ )  $< 90\%$ ,  $\geq 50\%$  fraction of inspired oxygen for  $> 1$  hour, intubation (other than for caesarean section) and pulmonary oedema.

### **Echocardiographic assessment**

All participants were studied by standard two-dimensional and Doppler transthoracic echocardiography at rest. Women were studied in the left lateral decubitus position and data were acquired at end-expiration from standard parasternal/apical views using a GE Vivid (GE Medical Systems Ltd, Chalfont St Giles, UK) or Philips (Philips Electronics UK, Farnborough, UK) scanner. For each acquisition, three cardiac cycles of non-compressed data were stored in cine-loop format and analysed by one investigator (JOD), who was masked to the group allocation, with a second read as described above. Cardiac indices were normalised for body surface area, height and end-diastolic left ventricle long- or short-axis lengths, as appropriate. Tissue Doppler imaging, strain and strain rate indices are given as absolute values. Details of measurements of heart remodelling, systolic and diastolic dysfunction are also described.

### **Myocardial necrosis assessment**

Participants were also consented to at least two blood sampling time points, most commonly performed at initial recruitment and the 6-month postpartum assessment. These samples were analysed for markers of myocardial necrosis/ischaemia: highly sensitive cardiac troponin-I. High-sensitivity troponin-I concentration in patients with stable cardiovascular disease identify those at increased risk of future myocardial infarction and other ischaemic cardiac outcomes (McQueen MJ, Kavsak PA, Xu L, Shestakovska O, Yusuf S. Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. *Clin Biochem* 2013;46:5–9). A sex-specific level of > 16 ng/l of high-sensitivity troponins was considered to be an elevated level in women. Cardiac myosin-binding protein C was also measured at 6 months postpartum using Singulex's (Alameda, CA, USA) Single Molecule Counting Technology SMC™, a quantitative fluorescent sandwich immunoassay technique. The level of a third biomarker, N-terminal pro-brain natriuretic peptide (a marker used in the assessment of patients with heart failure), was also assessed at 6 months postpartum.

### **Statistical analysis**

Assuming an anticipated incidence of 70% of women with preterm pre-eclampsia having evidence of systolic and/or diastolic dysfunction at 6 months postpartum, a sample size of 322 women was needed to detect a 25% relative risk reduction (from 70% to 52.5%; deemed clinically important) in the primary outcome in the planned delivery group compared with those managed expectantly with a two-sided 5% significance level and 90% power. With a 20% loss of women at follow-up, the overall target for recruitment was 404 women (202 per group). The primary analysis for all maternal outcomes was by intention to treat, with participants analysed in the groups to which they were assigned regardless of protocol non-compliance. Risk ratios were estimated for binary outcomes with associated 95% confidence intervals. Simple and multiple regression analysis were used to assess the influence of early pregnancy factors, including blood pressure, demographic variables (maternal age, body mass index), pregnancy characteristics (parity, gestation at delivery, gestation at onset and severity of pre-eclampsia), on indices of cardiac function and remodelling, as detailed above (see *Outcomes*). All of the conventional echocardiographic indices were adjusted for body surface area and all of the tissue Doppler velocity and deformation indices to the end-diastolic left or right ventricle long-axis length. Prespecified subgroup analyses were carried out for co-primary outcomes in view of the changes to definitions of systolic and diastolic dysfunction over the study period. Data analyses were carried out with Stata/SE® (StataCorp LP, College Station, TX, USA) version 15.1.

## **Results**

Between 27 April 2016 and 30 November 2018, 623 women were found to be eligible, of whom 420 (67%) were recruited, across 28 maternity units in England and Wales. A total of 133 women were allocated to planned delivery, 137 women were allocated to expectant management and a further 150 received non-randomised expectant management.



For the intention-to-treat analysis, data from 100 women in the planned delivery group and from 107 women in the expectant management group were included. Follow-up to the 6-month postpartum assessments continued until 20 June 2019. Thirty-three (25%) women were lost to follow-up in the planned delivery group and 30 (22%) in the expectant management group. Baseline characteristics appeared similar between the two groups, with groups well balanced on minimisation factors.

There were no differences in the primary outcome between women in the planned delivery group (50%) compared with those in the expectant management group (47.2%) using either the 2009 (risk ratio 1.06, 95% confidence interval 0.80 to 1.40) or the 2016 definition (8.0% vs. 10.3%; risk ratio 0.78, 95% confidence interval 0.33 to 1.86). No between-group differences were observed in 2009 diastolic dysfunction grade 1 (risk ratio 1.40, 95% confidence interval 0.59 to 3.31), grade 2 (risk ratio 1.11, 95% confidence interval 0.78 to 1.57) or grade 3 (risk ratio 1.18, 95% confidence interval 0.08 to 18.43) diastolic dysfunction subclassifications nor in 2016 diastolic dysfunction classification. Overall, 10% (31/321) of women had a left ventricular ejection fraction < 55% 6 months postpartum. Similarly, using the more recent 2016 classification for systolic and diastolic dysfunction, no differences were observed in systolic (risk ratio 0.76, 95% confidence interval 0.32 to 1.80) or any of the diastolic dysfunction parameters. Hypertension prevalence, defined as on antihypertensive treatment or systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at 6 months postpartum, was similar between those managed with planned delivery and those expectantly managed (risk ratio 1.01, 95% confidence interval 0.85 to 1.20) but, overall, was present in 71% of the cohort. No significant differences were observed in any of the cardiac parameters including geometric and haemodynamic parameters, left ventricular global cardiac parameters, myocardial mechanics and left ventricular basal or apical parameters between those women with planned delivery and those who were expectantly managed.

The only variables that were predictive of systolic and/or diastolic dysfunction at 6 months postpartum were maternal body mass index (adjusted odds ratio 1.33 per 5 kg/m<sup>2</sup>, 95% confidence interval 1.12 to 1.59 per 5 kg/m<sup>2</sup>) and maternal age (adjusted odds ratio 2.16, 95% confidence interval 1.44 to 3.22 per 10 years). The interval from study enrolment to delivery was not associated with development of the primary outcome. All women in the planned delivery group received the trial intervention, although this was not always initiated within 48 hours as intended. Of women allocated to the planned delivery group, 105 (78%) out of 133 had delivery initiated within 48 hours.

Overall, 8% ( $n = 25$ ) of women had their clinical echocardiograms escalated by the trial cardiologist with clinical follow-up recommended. These were for a combination of structural ( $n = 8$ ), valvular ( $n = 8$ ), functional ( $n = 9$ ) or combined ( $n = 2$ ) findings. These clinical escalations accounted for 12% of those with the primary outcome, with 88% of those with systolic and/or diastolic dysfunction not requiring clinical escalation.

## Conclusions

In this randomised controlled trial of women with late preterm pre-eclampsia, planned delivery did not reduce cardiovascular dysfunction at 6 months postpartum. The adverse cardiovascular sequelae of preterm pre-eclampsia are substantial; 10% of women with preterm pre-eclampsia had a left ventricular ejection fraction < 55%, 71% remained hypertensive and 49% of women had evidence of impaired diastolic dysfunction of undetermined long-term clinical importance at 6 months postpartum. Women in the planned delivery group had a median shortening of pregnancy from enrolment to delivery of 4 days, but this did not result in decreased hypertension or cardiovascular dysfunction compared with those managed with usual care by expectant management. Only elevated body mass index and a higher age at enrolment predicted the occurrence of postpartum systolic and/or diastolic dysfunction.

Our finding of 71% of women with preterm pre-eclampsia remaining hypertensive 6 months postpartum is higher than reported in larger population-based cohorts, highlighting high levels of presumed undiagnosed hypertension. It is imperative that we understand the mechanisms that contribute to worsening risk factor profiles in young women to reduce future cardiovascular morbidity and mortality.

Our study confirms that pre-eclampsia is associated with substantial postpartum cardiovascular dysfunction, not influenced by expectant management or planned delivery. Pre-eclampsia should not be considered a self-limiting disease of pregnancy alone. This research improves our understanding of the mechanistic processes linking pre-eclampsia with maternal cardiovascular impairment. The evidence suggests that expectant management of preterm pre-eclampsia does not worsen postpartum cardiovascular dysfunction and women can be reassured that prolongation of a pregnancy affected by preterm pre-eclampsia will not further worsen their cardiovascular health. The study informs counselling of women with pre-eclampsia around future risks and also identifies the postpartum period as a critical area to target in future intervention studies. This study provides a body of evidence for postpartum cardiac functional impairment and demonstrates the need for further research into early intervention, particularly relating to novel therapeutic pathways.

## Recommendations for research

1. What postnatal interventions are effective in reducing cardiovascular dysfunction following preterm pre-eclampsia?
2. How can biomarker discovery improve prediction of cardiovascular dysfunction following adverse pregnancy outcomes?

## Trial registration

This trial is registered as ISRCTN01879376.

## Funding

This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in *Efficacy and Mechanism Evaluation*; Vol. 8, No. 12. See the NIHR Journals Library website for further project information.



# Chapter 1 Introduction

Pre-eclampsia affects 3–5% of pregnancies, complicating approximately 35,000 pregnancies in the UK every year. Cardiovascular disease is the leading cause of mortality in women in the UK.<sup>1</sup> Hypertensive disorders of pregnancy, in particular preterm pre-eclampsia, have been shown to be associated with an increased risk of development of a wide range of cardiovascular diseases, with increases in incidences observed as soon as 1 year postpartum.<sup>2</sup> The absolute risk that a woman with pre-eclampsia would develop a cardiovascular event including hypertension, ischaemic heart disease, stroke or venous thromboembolism when she reaches the age of 50–59 years is estimated to be 17.8%, compared with 8.3% in those without pre-eclampsia.<sup>3</sup> The American Heart Association now recognises pre-eclampsia as an independent risk factor for future cardiovascular disease.<sup>4</sup> The economic burden of cardiovascular disease is substantial; the British Heart Foundation estimated that in 2006 cardiovascular disease cost the NHS £14.3B and the UK economy £30.6B,<sup>5</sup> and the cost for EU health-care systems related to cardiovascular disease is estimated at €110B, approximately 10% of the total health-care expenditure across the EU. With an increasingly ageing population, costs are set to rise further.

To date, only case-control studies and small single-centre cohort studies exist to provide evidence of association between pre-eclampsia and persistent cardiovascular dysfunction. Although some women have pre-existing risk factors for pre-eclampsia that also predispose to cardiovascular disease and for whom pre-eclampsia may accelerate progression through adding a further stress, in others, pre-eclampsia occurs with no pre-existing factors and may be the first 'hit' in the pathway. The most likely explanation for the additional impact from pre-eclampsia is subclinical myocardial injury caused by the underlying pathophysiology. This proposed research seeks to elucidate the role and extent of myocardial stress in determining subsequent cardiac dysfunction.

The Pre-eclampsia in HOspital: Early iNduction or eXpectant management (PHOENIX) study, a multicentre randomised controlled trial, recruited women with late preterm pre-eclampsia who were 34 weeks' gestation to less than 37 weeks' gestation and having a singleton or dichorionic diamniotic twin pregnancy.<sup>6</sup> It demonstrated that initiation of planned delivery within the subsequent 48 hours after randomisation reduced severe maternal adverse outcomes with no difference in neonatal morbidity (but there were more neonatal unit admissions) compared with the current practice of expectant management until 37 weeks' gestation. This PHOENIX study provided a key opportunity to examine the mechanisms underlying cardiovascular dysfunction following a randomised intervention on timing of delivery. An associated editorial alongside the main trial publication questioned whether initiating delivery in late preterm pre-eclampsia rather than waiting until term might theoretically reduce the stress on the woman's cardiovascular system.<sup>7</sup> The editorial advised evaluating whether or not a change to active delivery of women with late preterm pre-eclampsia would also benefit maternal cardiovascular health in the long term.

We conducted a follow-up cardiovascular assessment of women eligible for the PHOENIX study to examine the hypothesis that planned delivery in women with preterm pre-eclampsia, with attendant myocardial ischaemia, may decrease the risk of the development of cardiovascular dysfunction following pregnancy. The main aim of this mechanistic study was to examine the effects of shortening pregnancy complicated by pre-eclampsia on cardiovascular function at 6 months postpartum by studying women enrolled in a randomised controlled trial of planned delivery compared with those undergoing usual care (expectant management) who had late preterm pre-eclampsia.



## Chapter 2 Methods

### Study design and participants

In this parallel-group, non-masked, multicentre, randomised controlled trial, we compared cardiovascular function at 6 months postpartum in women with preterm pre-eclampsia who were managed by planned delivery with women managed by expectant management (usual care). This trial was carried out in 28 consultant-led maternity units in England and Wales. Participants who were eligible for the PHOENIX study were approached following their decision to participate. A pregnant woman was eligible if she was between 34<sup>+0</sup> and 36<sup>+6</sup> weeks' gestation, had a diagnosis of pre-eclampsia or superimposed pre-eclampsia (as defined by the International Society for the Study of Hypertension in Pregnancy),<sup>8</sup> with a singleton or dichorionic diamniotic twin pregnancy and at least one viable fetus, was aged  $\geq 18$  years, and was able to give written informed consent. The only exclusion criterion to study participation was if a decision had already been made to deliver her baby in the next 48 hours. There were no substantial changes to the published study design, methods or outcomes after the start of the trial. The trial was approved by the South Central – Hampshire B Research Ethics Committee (number 13/SC/0645).

### Randomisation and masking

Participants were randomly assigned to planned delivery or expectant care in a 1 : 1 ratio, as previously described.<sup>6</sup> When women declined participation in the PHOENIX study, participation in the PHOEBE study was offered and these women were included as a third, non-randomised expectant (usual-care) group. The intervention was not masked from women, clinicians or data collectors because of the nature of the intervention. Trial statisticians were also not masked to allocation. However, the trial echocardiographer (JOD) was blinded to allocation group in analysis of all echocardiograms.

### Procedures

Women were approached for participation into the PHOENIX study. Regardless of their participation in the PHOENIX study, site research teams approached women to confirm their eligibility and to provide verbal and written information. A trained research midwife or clinician obtained written informed consent. A research team member entered baseline data on a web-based database. All other aspects of pregnancy management were expected to be in accordance with the UK national guidelines at the discretion of the responsible clinician.<sup>9</sup> Outcomes were recorded on the web-based trial database through case note review by trained researchers after maternal primary hospital discharge. Women were invited to return to their local hospital at least 6 months following delivery for echocardiography assessment, which was performed within an 8-week window. At this assessment, a brief medical history was recorded, blood pressure was assessed, and venepuncture and echocardiography were undertaken. Echocardiography was performed locally in accordance with a standard operating procedure circulated by the research team. Anonymised echocardiography discs were then sent to the lead echocardiographer (JOD), who analysed each echocardiogram without knowledge of trial allocation and entered results into the web-based trial database. Every tenth echocardiogram was second read, again masked to trial allocation, by an echocardiographer at the University of Oxford and the findings were compared by the trial lead cardiologist (PL) to ensure consistency. When echocardiography assessment demonstrated potentially concerning features that may have an impact on clinical care, the findings were escalated and reviewed by the lead cardiologist (PL) and communicated back to the lead clinician at the recruiting site with a clinical recommendation for follow-up.

## Outcomes

The primary outcome was a composite of diastolic and systolic function at 6 months postpartum classified according to the joint recommendation by the American Society of Echocardiography and the European Association of Cardiovascular Imaging as assessed by transthoracic echocardiography with tissue Doppler studies classified originally in 2009<sup>10</sup> and reclassified prior to study completion in 2016.<sup>11</sup> Tissue Doppler velocity and deformation indices have been shown to be highly sensitive at detecting even mild myocardial damage.<sup>12-15</sup> The primary outcome was chosen to integrate the subclinical myocardial injury that occurs in the long term as well as that resulting from the different time exposed to pre-eclampsia resulting from the randomised intervention in the PHOENIX study. The cardiovascular components from the maternal morbidity composite outcome in the PHOENIX study included severe hypertension post randomisation (systolic blood pressure  $\geq 160$  mmHg on at least one occasion), positive inotropic support, infusion of a third parenteral antihypertensive drug, myocardial ischaemia or infarction, oxygen saturation ( $SpO_2$ )  $< 90\%$ ,  $\geq 50\%$  fraction of inspired oxygen ( $FI_{O_2}$ ) for  $> 1$  hour, intubation (other than for caesarean section) and pulmonary oedema. The composite was chosen as an internationally accepted validated method for predicting adverse maternal outcome from pre-eclampsia.<sup>16</sup>

## Echocardiographic assessment

All participants were studied by standard two-dimensional and Doppler transthoracic echocardiography at rest. Women were studied in the left lateral decubitus position and data were acquired at end-expiration from standard parasternal/apical views using a GE Vivid (GE Medical Systems Ltd, Chalfont St Giles, UK) or Philips (Philips Electronics UK, Farnborough, UK) scanner.<sup>10,17</sup> For each acquisition, three cardiac cycles of non-compressed data were stored in cine-loop format and analysed by one investigator (JOD), who was masked to the group allocation, with a second read as described above. Cardiac indices were normalised for body surface area, height and end-diastolic left ventricle long or short axis lengths, as appropriate.<sup>18-20</sup> Tissue Doppler imaging (TDI), strain and strain rate indices are given as absolute values.

## Heart remodelling

Chamber quantification and left ventricular geometric pattern were estimated using M-mode, as previously described.<sup>17</sup> Proximal septal bulging was assessed in the parasternal long-axis and apical four-chamber views.<sup>21</sup>

## Systolic and diastolic dysfunction

Global left ventricular diastolic function, estimated filling pressures on the left side of the heart and geometry were assessed and graded using standard diagnostic algorithms with the recommended adjustments reflecting the concomitant systolic function and age.<sup>22</sup> Left ventricular volumes and ejection fractions were derived from Simpson's modified biplane method from apical four-chamber and two-chamber views, and left ventricular systolic dysfunction was defined as ejection fraction  $< 55\%$ .<sup>17</sup> Haemodynamic and systolic cardiac indices were calculated as previously described.<sup>23</sup> Longitudinal and radial systolic function were assessed both globally and regionally using colour and pulsed tissue Doppler velocity indices and strain rate indices using speckle tracking, as previously described.<sup>24-28</sup> Regional peak systolic strain rate index was considered abnormal if it was two standard deviations below the expected mean for age.<sup>29</sup> This abnormality was defined as segmental myocardial impaired contractility. Regional diastolic dysfunction was defined as early to late strain rate ratio  $< 1$ . This abnormality was defined as segmental impaired myocardial relaxation. Maternal blood pressure was measured following the recommendations of the International Society for the Study of Hypertension in Pregnancy and National High Blood Pressure Education Programme Working Group on High Blood Pressure in Pregnancy.<sup>30,31</sup>

The left ventricular global systodiastolic dysfunction was defined as left ventricular global diastolic dysfunction in the presence of reduced ejection fraction (< 55%). Function and remodelling of the right heart were assessed using conventional echocardiography, tissue Doppler and myocardial deformation indices following published guidelines. The severity of left and right ventricular hypertrophy and dysfunction was graded according to the European Association and American Society of Echocardiography guidelines,<sup>10,17</sup> with the following adjustments described by Melchiorre *et al.*:<sup>24</sup> age, increased circulating volume in pregnancy, and the acute nature of pre-eclampsia on a previously normal cardiovascular system. For our primary outcome, diastolic dysfunction was classified as normal, impaired myocardial relaxation with normal left ventricular end-diastolic pressure (grade 1), pseudonormal filling pattern (grade 2) and restrictive pattern (grade 3).<sup>24</sup> Findings were also reported in accordance with ASE/EACVI 2016 guidelines,<sup>11</sup> published after study conception and the start of recruitment.

Secondary outcomes included systolic blood pressure and diastolic blood pressure at 6 months postpartum, together with the cardiovascular components of the fullPIERS composite maternal morbidity outcome adapted from the fullPIERS prediction of adverse events in pre-eclampsia study.<sup>16,32</sup>

## Myocardial necrosis assessment

Participants were also consented to at least two blood sampling time points, most commonly performed at initial recruitment and the 6-month postpartum assessment. These samples were analysed for markers of myocardial necrosis/ischaemia: highly sensitive cardiac troponin-I (cTnIs). High-sensitivity troponin concentrations in patients with stable cardiovascular disease identify those at increased risk for future myocardial infarction and other ischaemic cardiac outcomes.<sup>33</sup> A sex-specific level of > 16 ng/l of high-sensitivity troponins was considered to be an elevated level in women.<sup>34</sup> Cardiac myosin-binding protein C (cMyC) was also measured at 6 months postpartum using Singulex's Single Molecule Counting Technology SMC™, a quantitative fluorescent sandwich immunoassay technique. A third biomarker, N-terminal pro-brain natriuretic peptide, a marker used in the assessment of patients with heart failure, was also assessed at 6 months postpartum.

## Statistical analysis

Assuming an anticipated incidence of 70% of women with preterm pre-eclampsia having evidence of systolic and/or diastolic dysfunction at 6 months postpartum,<sup>24,35,36</sup> a sample size of 322 women was needed to detect a 25% relative risk reduction (from 70% to 52.5%; deemed clinically important) in the primary outcome in the planned delivery group compared with those managed expectantly with a two-sided 5% significance level and 90% power. With a 20% loss of women at follow-up, the overall target for recruitment was 404 women (202 per group). The primary analysis for all maternal outcomes was by intention to treat with participants analysed in the groups to which they were assigned regardless of protocol non-compliances. Power calculations were carried out in Stata® (StataCorp LP, College Station, TX, USA) version 13.1.

Risk ratios were estimated for binary outcomes with associated 95% confidence intervals (CIs). Simple and multiple regression analysis were used to assess the influence of early pregnancy factors, including blood pressure, demographic variables [maternal age, body mass index (BMI)], pregnancy characteristics (parity, gestation at delivery, gestation at onset and severity of pre-eclampsia), on indices of cardiac function and remodelling, as detailed above (see *Outcomes*). All of the conventional echocardiographic indices were adjusted for body surface area<sup>17</sup> and all of the tissue Doppler velocity and deformation indices to the end-diastolic left or right ventricle long-axis length.<sup>18</sup> Prespecified subgroup analyses were carried out for co-primary outcomes in view of the changes to definitions of systolic and diastolic dysfunction over the study period. Data analyses were carried out with Stata/SE version 15.1.





## Chapter 3 Results

Between 27 April 2016 and 30 November 2018, 623 women were found to be eligible, of whom 420 (67%) were recruited, across 28 maternity units in England and Wales. A total of 133 women were allocated to planned delivery, 137 women were allocated to expectant management and a further 150 received non-randomised expectant management (Figure 1).

For the intention-to-treat analysis, data from 100 women in the planned delivery group and 107 women in the expectant management group were included. Follow-up to the 6-month postpartum assessments continued until 20 June 2019. Thirty-three (25%) women were lost to follow-up in the planned delivery group and 30 (22%) in the expectant management group (see Figure 1). Baseline characteristics appeared similar between the two groups, with groups well balanced on minimisation factors (Table 1).

The enrolment characteristics are shown in Table 2.




FIGURE 1 Participant flow chart. a, 28 women did not receive initiation of planned delivery within 48 hours due to clinical decision ( $n = 2$ ), labour ward being too busy ( $n = 15$ ), a shortage of neonatal cots ( $n = 5$ ), or other reasons ( $n = 6$ ).

## RESULTS

**TABLE 1** Baseline maternal demographic and pregnancy characteristics at trial entry for all women who underwent 6-month echocardiography (*n* = 321)

	Planned delivery ( <i>N</i> = 100)	Expectant management (randomised) ( <i>N</i> = 107)	Expectant management (non-randomised) ( <i>N</i> = 114)
Age at randomisation (years), mean (SD)	30.56 (6.11)	31.26 (6.14)	32.81 (5.18)
Ethnicity, <i>n</i> (%)			
White	76 (76.0)	83 (77.6)	70 (61.4)
Asian	13 (13.0)	10 (9.3)	19 (16.7)
Black	8 (8.0)	6 (5.6)	20 (17.5)
Mixed	2 (2.0)	6 (5.6)	2 (1.8)
Other	1 (1.0)	2 (1.9)	3 (2.6)
Deprivation Index quintile, <i>n</i> (%)			
1 (most deprived)	38 (38.0)	39 (36.4)	46 (40.4)
2	23 (23.0)	28 (26.2)	26 (22.8)
3	14 (14.0)	12 (12.1)	19 (16.7)
4	13 (13.0)	20 (18.7)	18 (15.8)
5 (least deprived)	12 (12.0)	7 (6.5)	5 (4.4)
Parity (previous pregnancies $\geq$ 24 weeks' gestation), <sup>a</sup> <i>n</i> (%)			
0	64 (64.0)	68 (64)	75 (66)
1	24 (24.0)	19 (18)	26 (23)
2	4 (4.0)	11 (10)	7 (6)
> 2	8 (8.0)	9 (8)	6 (5)
Previous pregnancies < 24 weeks' gestation, <i>n</i> (%)			
0	22 (39.3)	23 (46.0)	21 (35.6)
1	19 (33.9)	14 (28.0)	28 (47.5)
2	11 (19.6)	8 (13.0)	5 (8.5)
> 2	4 (7.1)	5 (10.0)	5 (8.5)
Previous caesarean section, <sup>a</sup> <i>n</i> (%)	13 (13)	19 (18)	20 (34)
History of pre-eclampsia, <i>n</i> (%)	15 (15)	17 (16)	19 (17)
BMI at booking (kg/m <sup>2</sup> ), mean (SD)	30.2 (9.0)	30.0 (7.4)	30.3 (6.2)
Smoking status at booking, <i>n</i> (%)			
Never smoked	81 (81)	79 (73.8)	97 (85.1)
Quit before booking	14 (14)	22 (20.6)	11 (9.6)
Smoking at booking	5 (5.0)	6 (5.6)	6 (5.3)
Blood pressure 48 hours prior to enrolment (mmHg), <sup>a</sup> <i>n</i> (%)			
Systolic (mean, SD)	153 (15)	155 (15)	154 (15)
Diastolic (mean, SD)	96 (10)	96 (11)	94 (9)

SD, standard deviation.

<sup>a</sup> Minimisation factors used in the PHOENIX study to ensure balance at randomisation.

TABLE 2 Maternal clinical characteristics for women with primary outcome

	Planned delivery (N = 100)	Expectant management (randomised) (N = 107)	Expectant management (non-randomised) (N = 114)
Gestational age at enrolment <sup>a</sup> (weeks)			
Median (IQR)	35.6 (34.9–36.2)	35.6 (34.7–36.1)	34.4 (34.4–34.4)
34 <sup>+0</sup> to 34 <sup>+6</sup> , n (%)	28 (28.0)	32 (29.9)	46 (40.4)
35 <sup>+0</sup> to 35 <sup>+6</sup> , n (%)	34 (34.0)	38 (35.5)	35 (30.7)
36 <sup>+0</sup> to 36 <sup>+6</sup> , n (%)	38 (38.0)	37 (34.6)	33 (28.9)
Pregnancy type, <sup>a</sup> n (%)			
Singleton	90 (90.0)	96 (89.7)	110 (96)
Twin	10 (10.0)	11 (10.3)	4 (4)
Comorbidity at study entry (non-exclusive), n (%)			
Pre-existing chronic hypertension	11 (11.0)	13 (12.1)	13 (11.4)
Pre-existing chronic renal disease	2 (2.0)	1 (0.9)	0 (0.0)
Pre-pregnancy diabetes	6 (6.0)	3 (2.8)	9 (7.9)
Gestational diabetes	14 (14.0)	12 (11.2)	14 (12.3)
Severity of hypertension in 48 hours prior to enrolment <sup>ab</sup> (mmHg)			
Systolic BP, mean (SD)	153 (14)	155 (15)	154 (15)
Diastolic BP, mean (SD)	96 (10)	96 (10)	94 (9)
≤ 149, n (%)	41 (41.0)	38 (35.5)	45 (39.5)
150–159, n (%)	28 (28.0)	34 (31.8)	29 (25.4)
≥ 160, n (%)	31 (31.0)	35 (32.7)	40 (35.1)
Oral antihypertensive medications at study entry, n (%)			
0 agents	21 (21.0)	15 (14.0)	17 (14.9)
1 agent	53 (53.0)	59 (55.1)	59 (51.8)
≥ 2 agents	26 (26.0)	33 (30.8)	38 (33.3)
Aspirin prescribed during pregnancy, n (%)	47 (47.0)	42 (39.3)	49 (43.0)
LMWH prescribed at enrolment, n (%)	32 (32.0)	38 (35.5)	44 (38.6)
Most recent lab parameters prior to study entry, mean (SD)			
Protein-creatinine ratio (mg/mol)	137 (160)	210 (389)	128 (151)
Haemoglobin (g/l)	117 (11)	117 (12)	115 (12)
Platelets (×10 <sup>9</sup> /l)	228 (101)	207 (52)	217 (65)
Creatinine (μmol/l)	58 (14)	61 (12)	63 (15)
Alanine aminotransferase (U/l)	25 (28)	22 (34)	30 (43)
Aspartate aminotransferase (U/l)	125 (295)	20 (9)	22 (18.31)
Suspected fetal growth restriction, n (%)	22 (27.8)	20 (20.4)	21 (20.6)

continued

## RESULTS

TABLE 2 Maternal clinical characteristics for women with primary outcome (continued)

	Planned delivery (N = 100)	Expectant management (randomised) (N = 107)	Expectant management (non-randomised) (N = 114)
Antenatal ultrasound findings, n (%)			
AC < 10th	5 (6.3)	4 (4.1)	5 (6.3)
EFW < 10th	18 (22.8)	19 (19.4)	17 (16.7)
Umbilical artery PI > 95th	5 (6.3)	1 (1.0)	3 (2.9)
AREDF	0 (0.0)	0 (0.0)	2 (2.0)
AFI < 5th	2 (2.5)	1 (1.0)	2 (2.0)
Inpatient at time of trial entry			
Yes	75 (75.0)	90 (84.1)	97 (85.1)
Biomarkers at enrolment			
Highly sensitive cardiac troponin-I, median (IQR) (ng/l)	5 (5–5)	5 (5–6)	5 (5–6)
> 16 ng/l, n (%)	0 (0)	2 (1.9)	4 (3.6)

AC, abdominal circumference; AFI, amniotic fluid index; AREDF, absent to reverse end-diastolic flow; BP, blood pressure; EFW, estimated fetal weight; IQR, interquartile range; LMWH; low-molecular-weight heparin; PI, pulsatility index; SD, standard deviation.

a Minimisation factors used to ensure balance at randomisation.

b These are summary statistics for the mean of an individual's two BP readings.

There were no differences between women in the planned delivery group compared with the expectant management group in the primary outcome using either the 2009<sup>10</sup> [risk ratio (RR) 1.06, 95% confidence interval (CI) 0.80 to 1.40] or the 2016 definition<sup>11</sup> (RR 0.78, 95% CI 0.33 to 1.86), shown in Table 3. No between-group differences were observed in 2009 diastolic dysfunction grade 1 (RR 1.40, 95% CI 0.59 to 3.31), grade 2 (1.11, 95% CI 0.78 to 1.57) or grade 3 (1.18, 95% CI 0.08 to 18.43) diastolic dysfunction subclassification nor in 2016 diastolic dysfunction classification. Overall, 10% (31/321) of

TABLE 3 Primary and secondary outcomes at 6 months postpartum

	Planned delivery (N = 100)	Expectant management (randomised) (N = 107)	Effect measure, <sup>b</sup> RR (95% CI)	All recruited women (N = 321)
<b>Primary outcome (2009 definition),<sup>10</sup> n/N (%)</b>				
Diastolic and/or systolic dysfunction postpartum	50/100 (50.0)	50/106 (47.2)	1.06 (0.80 to 1.40)	164 (51)
Systolic dysfunction (yes/no) defined as left ventricular ejection fraction < 55%	8/98 (8.2)	11/102 (10.8)	0.76 (0.32 to 1.80)	31 (10)
<b>Diastolic dysfunction subclassification,<sup>a</sup> n (%)</b>				
Normal	N = 96	N = 103		
	48 (50.0)	57 (55.3)		157 (51)
Impaired myocardial relaxation with normal left ventricular end-diastolic pressure (grade 1)	10 (10.4)	8 (7.8)	1.40 (0.59 to 3.31)	27 (9)
Pseudonormal filling pattern (grade 2)	37 (38.5)	37 (35.9)	1.11 (0.78 to 1.57)	123 (40)
Restrictive pattern (grade 3)	1 (1.0)	1 (1.0)	1.18 (0.08 to 18.43)	3 (1)

TABLE 3 Primary and secondary outcomes at 6 months postpartum (continued)

	Planned delivery (N = 100)	Expectant management (randomised) (N = 107)	Effect measure, <sup>b</sup> RR (95% CI)	All recruited women (N = 321)
<b>Primary outcome (2016 definition),<sup>11</sup> n/N (%)</b>				
Diastolic and/or systolic dysfunction postpartum	8/100 (8.2)	11/107 (10.3)	0.78 (0.33 to 1.86)	31 (10)
Systolic dysfunction (yes/no) defined as left ventricular ejection fraction < 55%	8/98 (8.2)	11/102 (10.8)	0.76 (0.32 to 1.80)	31 (10)
Diastolic dysfunction (yes/no) (> 50%/≥ 3-4 positive)	1/100 (1.0)	0/107 (0.0)	NA	5 (2)
Average E/e' > 14	1/96 (1.0)	2/99 (2.0)	0.52 (0.05 to 5.59)	1 (1.0)
Septal e' velocity < 7 cm/second or lateral e' velocity < 10 cm/second	15/96 (15.6)	13/103 (12.6)	1.24 (0.62 to 2.46)	45 (14.0)
Tricuspid regurgitant velocity > 2.8 m/second	1/100 (1.0)	0/107 (0)	-	3 (0.9)
Left atrial volume index (> 34 ml/m <sup>2</sup> )	4/98 (4.1)	3/106 (2.8)	1.44 (0.33 to 6.28)	13 (4.0)
<b>Diastolic dysfunction criteria present, n (%)</b>	<b>N = 100</b>	<b>N = 107</b>		
0	82 (82.0)	90 (84.1)		257 (80.0)
1+	16 (16.0)	16 (15.0)	-	58 (18.0)
2+	1 (1.0)	1 (0.9)	-	5 (2.0)
≥ 3+	1 (1.0)	0 (0.0)	-	1 (0)
<b>Secondary outcomes</b>				
<b>Haemodynamic, mmHg [mean (SD)]</b>	<b>N = 100</b>	<b>N = 107</b>		
Systolic blood pressure	124 (14)	123 (17)	1.48 (-2.88 to 5.85)	123 (16)
Diastolic blood pressure	76 (13)	75 (13)	-0.59 (-2.96 to 4.14)	76 (13)
Hypertension prevalence (on antihypertensive treatment with or without systolic BP > 140 mmHg with or without diastolic BP > 90 mmHg)	72 (72)	76 (71)	1.01 (0.85 to 1.20)	229 (71)
<b>Biomarkers at 6-month follow-up, n (%)</b>	<b>N = 92</b>	<b>N = 100</b>		
Highly sensitive cTnI > 16 ng/l	1 (1)	1 (1)	1.09 (0.07 to 17.13)	4 (1.4)
N-terminal pro-brain natriuretic peptide > 100 ng/l	10 (11)	15 (15)	0.72 (0.34 to 1.52)	38 (13.2)
cMyC > 87 ng/l	1 (1)	1 (1)	1.10 (0.07 to 17.31)	2 (0.7)
<b>Echocardiography parameters, mean (SD)</b>				
Relative wall thickness (ratio)	0.35 (0.06)	0.35 (0.07)	0.00 (-0.02 to 0.01)	0.35 (0.06)
Left ventricular mass index (g/m <sup>2</sup> )	63.3 (16.4)	66.7 (14.7)	-3.41 (-7.69 to 0.87)	65.1 (14.8)
LV mass (g)	122 (31)	128 (36)	-5.73 (-14.89 to 3.42)	125 (32)
Stroke volume (ml)	64.1 (10.5)	62.4 (11.6)	1.69 (-1.37 to 4.74)	62.6 (11.4)
Cardiac output (l/minute)	4.8 (0.9)	4.7 (1.0)	0.12 (-0.14 to 0.39)	

continued

## RESULTS

TABLE 3 Primary and secondary outcomes at 6 months postpartum (continued)

	Planned delivery (N = 100)	Expectant management (randomised) (N = 107)	Effect measure, <sup>b</sup> RR (95% CI)	All recruited women (N = 321)
<b>Geometric and haemodynamic parameters</b>				
<i>Left ventricular geometry, n (%)</i>	N = 100	N = 107		
Normal	84 (84)	88 (82)	Referent group	265 (83)
Concentric remodelling	14 (14)	18 (17)	0.84 (0.44 to 1.60)	53 (17)
Eccentric remodelling	2 (2)	1 (1)	2.07 (0.19 to 22.41)	3 (1)
<b>LV global cardiac parameters, mean (SD)</b>				
Left ventricular ejection fraction	57.9 (4.7)	58.4 (3.9)	-0.49 (-1.70 to 0.70)	58.5 (4.4)
E/A ratio	1.37 (0.41)	1.40 (0.43)	-0.02 (-0.14 to 0.09)	1.37 (0.39)
Average E/e'	6.95 (2.07)	7.24 (2.21)	-0.28 (-0.89 to 0.32)	7.07 (1.98)
Lateral e' velocity (cm/second)	0.14 (0.04)	0.14 (0.03)	0.00 (-0.01 to 0.01)	0.14 (0.03)
Septal e' velocity (cm/second)	0.10 (0.02)	0.10 (0.02)	0.00 (-0.01 to 0.01)	0.10 (0.02)
Tricuspid regurgitant velocity (m/second)	1.46 (0.79)	1.47 (0.83)	-0.01 (-0.23 to 0.21)	1.49 (0.79)
Left atrial volume index (ml/m <sup>2</sup> )	20.3 (6.6)	21.7 (6.5)	-1.42 (-3.22 to 0.39)	21.1 (6.7)
<b>Myocardial mechanics</b>				
<i>LV longitudinal parameters, mean (SD)</i>				
Peak global LV longitudinal strain (%)	-16.9 (3.4)	-16.9 (3.2)	-0.02 (-0.95 to 0.90)	-17.0 (3.3)
Peak global LV longitudinal strain rate (%·s <sup>-1</sup> )	-0.89 (0.2)	-0.9 (0.2)	0.03 (-0.03 to 0.08)	-0.89 (0.20)
<i>LV basal parameters, mean (SD)</i>				
Basal radial strain (%)	24.5 (15.1)	26.4 (18.3)	-1.95 (-6.59 to 2.70)	24.7 (16.0)
Basal radial strain rate (%·s <sup>-1</sup> )	1.42 (1.13)	1.43 (0.92)	0.00 (-0.29 to 0.28)	1.40 (0.95)
Basal circumferential strain (%)	-17.84 (5.82)	-17.32 (5.75)	-0.51 (-2.12 to 1.09)	-17.57 (5.98)
Basal circumferential strain rate (%·s <sup>-1</sup> )	-1.12 (0.37)	-1.09 (0.37)	-0.03 (-0.13 to 0.07)	-1.10 (0.38)
<i>LV apical parameters, mean (SD)</i>				
Apical radial strain (%)	25.1 (13.3)	24.9 (15.7)	-0.20 (-4.51 to 4.12)	24.8 (17.7)
Apical radial strain rate (%·s <sup>-1</sup> )	1.3 (1.1)	1.2 (0.6)	-0.14 (-0.40 to 0.12)	1.3 (0.9)
Apical circumferential strain (%)	-22.0 (7.3)	-21.6 (7.1)	0.34 (-1.78 to 2.47)	-21.6 (7.1)
Apical circumferential strain rate (%·s <sup>-1</sup> )	-1.3 (0.5)	-1.3 (0.4)	0.00 (-0.14 to 0.14)	-1.3 (0.5)
BP, blood pressure; cMyC, cardiac myosin binding protein C; LV, left ventricular; NA, not applicable.				
a Graded 1–3 using the median value from the classification of the variables E/A (early to late diastole peak transmitral velocity ratio), deceleration time of E wave (DT) and isovolumetric relaxation time (IVRT) into the following groups:				
<ul style="list-style-type: none"> <li>• E/A: &lt; 0.73; 0.73–2.33; &gt; 2.33</li> <li>• DT: &gt; 194 ms; 138–194 ms; &lt; 138 ms</li> <li>• IVRT; &gt; 83 ms; 51–83 ms; &lt; 51 ms</li> </ul>				
b Effect measure adjusted for gestational age at study entry.				
E/e' refers to the ratio of the peak early mitral inflow velocity (E) over the early diastolic mitral annular velocity (e'). As not every echocardiography parameter was available on each examination, individual denominators are shown where applicable.				

women had a left ventricular ejection fraction < 55% 6 months postpartum. Similarly, using the more recent 2016 classification for systolic and diastolic dysfunction, no differences were observed in systolic (RR 0.76, 95% CI 0.32 to 1.80) or any of the diastolic dysfunction parameters. Hypertension prevalence, defined as on antihypertensive treatment with or without systolic blood pressure > 140 mmHg and with or without diastolic blood pressure > 90 mmHg at 6 months postpartum, was similar between those managed with planned delivery and those expectantly managed (RR 1.01, 95% CI 0.85 to 1.20) but, overall, was present in 71% of the cohort. No significant differences were observed in any of the cardiac parameters including geometric and haemodynamic parameters, left ventricular global cardiac parameters, myocardial mechanics and left ventricular basal or apical parameters between those women with planned delivery and those who were expectantly managed (see Table 3). The high prevalence of systolic and/or diastolic dysfunction or persistent hypertension was not explained by pre-existing chronic hypertension because when these women were excluded ( $n = 37$ , 11%), systolic and/or diastolic dysfunction was evident in 49.5% of women and hypertension was evident in 68.7% of women.

Mean time from enrolment to delivery was 2.5 [standard deviation (SD) 1.9] days in the planned delivery group compared with 6.8 (SD 5.3) days in the expectant management group. No differences were observed between groups in cardiorespiratory outcomes prior to discharge from hospital nor in any systolic or diastolic blood pressure measurements (Table 4).

TABLE 4 Secondary outcomes at discharge following delivery

	Planned delivery (N = 100)	Expectant management (randomised) (N = 108)	Effect measure (95% CI)	All recruited women (N = 321)
<b>Cardiorespiratory outcomes prior to discharge from hospital</b>				
Positive inotropic support, n (%)	0 (0.0)	0 (0.0)	–	0 (0.0)
Infusion of a third parenteral antihypertensive drug, n (%)	0 (0.0)	0 (0.0)	–	1 (0.3)
Myocardial ischaemia or infarction, n (%)	1 (1.0)	0 (0.0)	–	1 (0.3)
SpO <sub>2</sub> < 90%, n (%)	1 (1.0)	0 (0.0)	–	1 (0.3)
≥ 50% FiO <sub>2</sub> for > 1 hour, n (%)	0 (0.0)	0 (0.0)	–	0 (0.0)
Intubation (other than for caesarean section), n (%)	0 (0.0)	0 (0.0)	–	0 (0.0)
Pulmonary oedema, n (%)	0 (0.0)	0 (0.0)	–	0 (0.0)
Time from enrolment to delivery (days) mean (SD)	2.5 (1.9)	6.8 (5.3)	MD –3.83 (–5.61 to –2.06)	5.7 (5.0)
Gestational age at delivery (weeks), mean (SD)	35.9 (0.8)	36.4 (1.0)	MD –0.55 (–0.80 to –0.29)	36.4 (1.0)
Highest systolic BP enrolment to delivery (mmHg), mean (SD)	156 (17)	164 (15)	MD –8.06 (–12.47 to –3.65)	162 (16)
Highest diastolic BP enrolment to delivery (mmHg), mean (SD)	94 (10)	97 (13)	MD –3.16 (–6.27 to –0.04)	96 (11)
Highest systolic BP delivery to hospital discharge (mmHg), mean (SD)	154 (15)	157 (17)	MD –3.58 (–7.99 to 0.83)	156 (16)
Highest diastolic BP delivery to hospital discharge (mmHg), mean (SD)	90 (13)	93 (14)	MD –3.09 (–6.84 to 0.66)	92 (13)
Birth centile, <sup>a</sup> median (IQR)	29.7 (10.0, 58.0)	17.4 (8.3, 50.6)	MedD 6.34 (–0.98 to 13.67)	23.8 (8.3, 54.3)

continued



## RESULTS

TABLE 4 Secondary outcomes at discharge following delivery (continued)

	Planned delivery (N = 100)	Expectant management (randomised) (N = 108)	Effect measure (95% CI)	All recruited women (N = 321)
Birth centile < 10th centile, n (%)	27 (24.5)	35 (29.7)	RR 0.83 (0.54 to 1.27)	105 (30.3)
Birth centile < 3rd centile, n (%)	7 (6.4)	9 (7.6)	RR 0.83 (0.32 to 2.16)	31 (9)

BP, blood pressure; IQR, interquartile range; MD, mean difference; MedD, median difference.  
 a Calculated using INTERGROWTH centiles.<sup>37</sup>

The only variables affecting development of systolic and/or diastolic dysfunction at 6 months postpartum (2009 definition)<sup>10</sup> were maternal BMI [adjusted odds ratio (OR) 1.33 per 5 kg/m<sup>2</sup>, 95% CI 1.12 to 1.59 per 5 kg/m<sup>2</sup>] and maternal age (adjusted OR 2.16, 95% CI 1.44 to 3.22 per 10 years) (Table 5). Interval from study enrolment to delivery was not associated with development of the primary outcome. There were no significant predictor variables for systolic and/or diastolic dysfunction at 6 months postpartum by the updated 2016 definition<sup>11</sup> (Table 6). Inclusion of antenatal values of highly sensitive cardiac troponin-I did not alter the results. All women in the planned delivery group received the trial intervention, although this was not always initiated within 48 hours as intended. Of the women allocated to the planned delivery group, 105 out of 133 (79%) had delivery initiated within 48 hours (see Figure 1).

TABLE 5 Effect of baseline characteristics on the development of cardiovascular dysfunction (2009 definition)<sup>10</sup> at 6 months postpartum (all women)

	Unadjusted OR (95% CI)	Adjusted OR (95% CI) <sup>a</sup>
<b>At enrolment variables</b>		
Systolic BP (per 10 mmHg)	1.000 (0.999 to 1.002)	1.000 (0.998 to 1.002)
Diastolic BP (per 10 mmHg)	1.001 (0.998 to 1.003)	1.001 (0.999 to 1.003)
Height (per 10 cm)	1.042 (0.768 to 1.414)	1.010 (0.736 to 1.386)
Weight (per 1 kg)	1.016 (1.004 to 1.027)	1.000 (0.969 to 1.031)
BMI (per 5 kg/m <sup>2</sup> )	1.294 (1.091 to 1.534)	<b>1.334 (1.118 to 1.592)</b>
Age (per 10 years)	2.034 (1.375 to 3.008)	<b>2.156 (1.444 to 3.217)</b>
Smoking status: current	1.797 (0.648 to 4.983)	1.773 (0.624 to 5.037)
cTnI at enrolment (> 16 ng/l)	0.993 (0.313 to 3.150)	1.044 (0.322 to 3.380)
<b>Post-enrolment variables</b>		
Time from study recruitment to delivery	0.873 (0.636 to 1.197)	0.986 (0.709 to 1.373)
Highest systolic BP enrolment to delivery (per 10 mmHg)	1.000 (0.999 to 1.002)	1.000 (0.999 to 1.002)
Highest diastolic BP enrolment to delivery (per 10 mmHg)	1.001 (0.999 to 1.003)	1.001 (0.999 to 1.003)
Adverse maternal event (dichotomous) <sup>b</sup>	1.148 (0.701 to 1.881)	1.155 (0.688 to 1.940)
Gestational age at delivery	0.993 (0.963 to 1.024)	0.990 (0.958 to 1.023)

BP, blood pressure.  
 a Adjusted for BMI and age.  
 b Adverse maternal event is defined using the PHOENIX study protocol as a composite of maternal morbidity adapted from the fullPIERS model for prediction of pre-eclampsia adverse events,<sup>16</sup> which will include central nervous system, cardiorespiratory, haematological, hepatic and renal outcomes, together with placental abruption, intensive care unit admission and confirmed severe systolic hypertension ( $\geq 160$ mmHg). In the PHOEBE study, the clinical event will not include confirmed severe systolic hypertension.

**Note**  
 Adjusted odds ratios in bold indicate significant odds ratios.

TABLE 6 Effect of baseline characteristics on the development of systolic and/or diastolic dysfunction (2016 definition)<sup>11</sup> at 6 months postpartum (*n* = 321)

	Unadjusted OR (95% CI)
<b>At enrolment variables</b>	
Systolic BP (per 10 mmHg)	0.999 (0.996 to 1.001)
Diastolic BP (per 10 mmHg)	0.999 (0.996 to 1.003)
Height (per 10 cm)	1.157 (0.688 to 1.949)
Weight (per 1 kg)	1.005 (0.988 to 1.023)
BMI (per 5 kg/m <sup>2</sup> )	1.058 (0.815 to 1.373)
Age (per 10 years)	1.161 (0.621 to 2.172)
Smoking status: current	1.310 (0.284 to 6.054)
<b>Post-enrolment variables</b>	
Time from study recruitment to delivery	0.958 (0.567 to 1.617)
Highest systolic BP enrolment to delivery (per 10 mmHg)	0.999 (0.997 to 1.001)
Highest diastolic BP enrolment to delivery (per 10 mmHg)	1.002 (0.998 to 1.005)
Adverse maternal event (dichotomous) <sup>a</sup>	0.677 (0.310 to 1.480)
Gestational age at delivery	1.018 (0.705 to 1.471)
BP, blood pressure.	
a Adverse maternal event is defined using the PHOENIX study protocol as a composite of maternal morbidity adapted from the fullPIERS model for prediction of pre-eclampsia adverse events, <sup>16</sup> which will include central nervous system, cardiorespiratory, haematological, hepatic and renal outcomes together with placental abruption, intensive care unit admission as well as confirmed severe systolic hypertension ( $\geq 160$ mmHg). In the PHOEBE study, the clinical event will not include confirmed severe systolic hypertension.	

Overall, 8% (*n* = 25) of women had their clinical echocardiograms escalated by the trial cardiologist with clinical follow-up recommended. These were for a combination of structural (*n* = 8), valvular (*n* = 8), functional (*n* = 9) or combined (*n* = 2) findings. These clinical escalations accounted for 12% of those with the primary outcome, with 88% of those with systolic and/or diastolic dysfunction not requiring clinical escalation.



## Chapter 4 Discussion

In this randomised controlled trial of women with late preterm pre-eclampsia, planned delivery did not reduce cardiovascular dysfunction at 6 months postpartum. The adverse cardiovascular sequelae of preterm pre-eclampsia are substantial; 10% of women with preterm pre-eclampsia had a left ventricular ejection fraction < 55%, 71% remained hypertensive and 49% of women had evidence of impaired diastolic dysfunction of undetermined long-term clinical importance 6 months postpartum. Women in the planned delivery group had a median shortening of pregnancy from enrolment to delivery of 4 days, but this did not result in decreased hypertension or cardiovascular dysfunction compared with those managed with usual care by expectant management. Only elevated BMI and higher age at enrolment predicted the occurrence of postpartum systolic and/or diastolic dysfunction.

Previous systematic reviews and meta-analyses describe an association between pregnancies complicated by pre-eclampsia and long-term adverse cardiovascular morbidity and mortality including hypertension, myocardial infarction (13-fold increase), major cardiovascular events (13-fold increase), heart failure (eightfold increase), stroke (14-fold increase) and death (sixfold increase). We are unaware of any published randomised controlled trials evaluating the impact of timing of delivery on subsequent maternal cardiovascular function. This large, multicentre trial represents contemporaneous management of women with late preterm pre-eclampsia followed up by detailed standardised blood pressure and echocardiography assessment at 6 months postpartum. Our cohort sample size (321 women) is, to our knowledge, considerably larger than that of any other postpartum cardiovascular study previously performed, and the involvement of 28 centres throughout the UK makes this representative of the UK pregnant population. The randomised design allowed us a unique opportunity to explore the impact of timing of delivery on postpartum cardiovascular function.

The strengths of this study include a sufficiently large sample of women with late preterm pre-eclampsia from 28 centres throughout the UK completing a detailed 6-month postpartum cardiovascular assessment to describe the burden of cardiovascular disease in this population, linking pre-eclampsia with longer-term cardiovascular disease. The trial was conducted to rigorous standards, with a prespecified protocol without changes. The findings are likely to be generalisable to similar health-care settings because it was undertaken in a large number of maternity units across England and Wales, with a diverse representation of women in terms of both demography and disease spectrum. More than half of the eligible women who were approached agreed to participate in the trial, which indicated agreement of equipoise in this scenario. Echocardiography was performed by multiple echocardiographers throughout England and Wales, representative of cardiology units throughout the NHS. We have reported all prespecified secondary outcomes, interpreting them cautiously.

The limitations of the trial include a change in the international definition of systolic and/or diastolic dysfunction, such that interpretation of the findings needs to be undertaken in the light of the prespecified 2009 definition<sup>10</sup> and the later 2016 definition.<sup>11</sup> Our results reflect systolic and diastolic definitions used first in 2009 and which were then updated in 2016. We acknowledge that there is an interim group with a left ventricular ejection fraction between 50% and 55% and further prospective follow-up would help our understanding of the implications of this impairment in women following pregnancy. We, a priori, utilised the independent definition of systolic and/or diastolic dysfunction for this particular patient group as defined by Melchiorre *et al.*,<sup>24</sup> adapted from recommendations of the European Association of Echocardiography and American Society of Echocardiography<sup>10</sup> with adjustments for age, the higher circulating volume in pregnancy and the acute nature of pre-eclampsia in an otherwise previously normal cardiovascular system.<sup>24</sup> Newer non-pregnant specific definitions (ASE/EACVI guidelines 2016)<sup>11</sup> result in lower prevalence of diastolic dysfunction if applied, but cardiovascular morbidity is still evident and prevalent. There was a relatively short difference of a median 4 days in those managed with planned delivery than in those managed expectantly, and it is likely that this difference may not have been sufficiently long to result in detectable differences in cardiovascular function at 6 months postpartum.

Approximately one-third of the women recruited for this study had declined participation in the PHOENIX study and as a result were included as a non-randomised expectant management (usual-care) group. Results across all groups were very similar. We did not recruit women with a healthy pregnancy, as our primary research question was whether or not shortening of pregnancy after diagnosis of preterm pre-eclampsia altered the prevalence of cardiovascular dysfunction at 6 months postpartum.

We considered sources of possible bias for our trial. Selection bias into the trial was unlikely because of the randomisation process, which included robust allocation sequence concealment such that determining the next allocation was not possible. Performance and detection bias were possible because it was not possible to mask the participating clinicians, the participating women or the data collectors because the timing of delivery was contained within maternity records where morbidity was recorded. However, the trial echocardiographer was masked to randomisation groups and each echocardiogram was therefore read independent of the knowledge of trial allocation.

There was expected attrition to the 6-month follow-up of around 20% in both groups, but data completeness of pregnancy outcomes was high (> 99%). The study was originally powered for an analysis of 322 women (161 women in two treatment groups). However, it became apparent that a group of eligible women chose not to consent to the main randomised comparison in the PHOENIX study but would consent for the observational PHOEBE study, with all women in this group following usual care, which was expectant management. The aims of the PHOEBE study were primarily to explore the mechanism behind the effect of the intervention (timing of delivery) and to provide an understanding of postpartum cardiovascular dysfunction after preterm pre-eclampsia. We acknowledge that this study was underpowered for examining the effect of the intervention. The primary outcome event rate was also lower than expected by both 2009<sup>10</sup> and 2016 guidelines.<sup>11</sup> For the evaluation of the effect of the intervention, the two randomised groups were compared. As there was no signal of a significant effect in the secondary outcomes that would suggest that we had missed an important difference in the primary outcome (likely to be related to the much shorter separation in time between randomisation and initiation of delivery between the two groups than anticipated), we also combined all women recruited to provide an overall cohort of 321 women in which to complete the prognostic assessment (see *Table 5*) and to present a detailed cardiovascular assessment on a large prospective cohort of women with preterm pre-eclampsia.

A recent systematic review summarised 36 studies of maternal cardiovascular function involving 815 women at time of disease with pre-eclampsia. This study demonstrated that increased vascular resistance and left ventricular mass were the most consistent findings in pre-eclampsia.<sup>38</sup> Differentiating features of a pregnancy complicated by pre-eclampsia from normal pregnancy include left ventricular wall thickness of  $\geq 1.0$  cm, exaggerated reduction in early diastole/atrial contraction and lateral  $e'$  of  $< 14$  cm/second, which are the markers of diastolic dysfunction. Reduced stroke volume, diastolic dysfunction and left ventricular remodelling are most marked in severe and early-onset pre-eclampsia.<sup>24,35,39</sup> Our finding of cardiovascular dysfunction and persistent hypertension in the majority of women following preterm pre-eclampsia is in keeping with other single-centre observational studies.<sup>40-49</sup> However, none was multicentre nor designed to examine different maternal delivery strategies. Our finding of 71% of women with preterm pre-eclampsia remaining hypertensive 6 months postpartum is higher than reported in larger population-based cohorts, highlighting high levels of presumed undiagnosed hypertension.<sup>50</sup> As the PHOENIX study has now reported, it is unlikely that the opportunity will arise for other investigators to examine whether or not timing of delivery has an impact on cardiovascular function using such a randomised approach. Developing accurate validated prognostic tools to best identify those at highest risk of cardiovascular dysfunction remains challenging, and postpartum intervention strategies must now be explored to reduce this cardiovascular burden of disease.

We have demonstrated that the burden of postpartum cardiovascular dysfunction following preterm pre-eclampsia in these women, not otherwise identified as having morbidity, is high. In low-resource health-care settings and developing countries where underdetected comorbidities including chronic

hypertension are high and cases of fulminant eclampsia prevalent (incidence 1.4%),<sup>51</sup> the burden of cardiovascular morbidity is likely much higher. Recent US data suggest stagnation in the improvements in incidence and mortality of cardiovascular disease, specifically among younger women.<sup>52</sup> It is imperative that we understand the mechanisms that contribute to worsening risk factor profiles in young women to reduce future cardiovascular morbidity and mortality. This is acknowledged in the 2030 Agenda for Sustainable Development,<sup>53</sup> which aims to reduce by one-third premature mortality from non-communicable diseases, with cardiovascular disease being the leading cause of death from such diseases.

Two decades of research have documented an association between pre-eclampsia and major cardiovascular disorders in later life.<sup>2,3,54,55</sup> Despite this body of evidence, usual practice after a pregnancy complicated by preterm pre-eclampsia is no specific follow-up. It is recognised by the Joint British Societies, which includes the British Cardiac Society, Heart UK and the British Hypertension Society, that pregnancy and infancy are good opportunities for education and intervention.<sup>56</sup> Furthermore, they endorse intensive risk factor lowering in individuals with high risk factors that cause cardiovascular disease. Women with preterm pre-eclampsia are at increased risk of cardiovascular disease later in life compared with those without preterm pre-eclampsia. In addition, compared with women without hypertension in pregnancy, women who have had one or more pregnancies affected by pre-eclampsia have been shown to have an increased hazard ratio of 1.9 (95% CI 1.53 to 2.35) for any stroke, 1.67 (95% CI 1.54 to 1.81) for cardiac atherosclerotic events, 1.82 (95% CI 1.34 to 2.46) for peripheral events, 2.13 (95% CI 1.64 to 2.76) for heart failure, 1.73 (95% CI 1.38 to 2.16) for atrial fibrillation, 2.12 (95% CI 1.49 to 2.99) for cardiovascular deaths and 4.47 (95% CI 4.32 to 4.62) for chronic hypertension.<sup>2</sup> This study has provided mechanistic information on how subsequent clinical cardiovascular events may be mediated through impaired cardiac function identifiable at 6 months after preterm pre-eclampsia and highlights the postpartum period as an opportunity for early intervention prior to sustained and irreversible damage. There is increasing interest in the role of lifestyle and therapeutic interventions (e.g. with angiotensin-converting enzyme inhibitors) to reduce subsequent cardiovascular risk. This study provides a body of evidence for postpartum cardiac functional impairment and demonstrates the need for further research into early intervention, particularly relating to novel therapeutic pathways.

In conclusion, our study confirms that late preterm pre-eclampsia is associated with substantial postpartum cardiovascular dysfunction. The relatively short delay in those expectantly managed (compared with planned delivery) does not worsen this cardiovascular dysfunction. Ten per cent of women with preterm pre-eclampsia had a left ventricular ejection fraction < 55%, 71% remained hypertensive and 49% of women had evidence of impaired diastolic dysfunction of undetermined long-term clinical importance 6 months postpartum. Further follow-up would be useful to understand the longer-term cardiovascular implications of these findings and whether these parameters relate to hypertension, age or increased BMI. Pre-eclampsia should not be considered a self-limiting disease of pregnancy alone. This research improves our understanding of the mechanistic processes linking pre-eclampsia with maternal cardiovascular impairment. The evidence suggests that expectant management of preterm pre-eclampsia does not worsen postpartum cardiovascular dysfunction, and women can be reassured that prolongation of a pregnancy affected by preterm pre-eclampsia will not further worsen their cardiovascular health. The study informs counselling of women with pre-eclampsia around future risks and also identifies the postpartum period as a critical area to target in future intervention studies.



# Acknowledgements

We thank Ursula Bowler and Pauline Rushby (University of Oxford); Eleanor Hendy and Emma Green (King's College London); Linda Arnold (University of Oxford); and all the participating women, site research midwives and doctors for their contribution to the study.

## Contributions of authors

**Fergus P McCarthy** (<https://orcid.org/0000-0001-5062-6851>) (Clinical Fellow, Obstetrics and Gynaecology), **Jamie O'Driscoll** (<https://orcid.org/0000-0002-5923-4798>) (Senior Lecturer, Exercise Physiology), **Paul Seed** (<https://orcid.org/0000-0001-7904-7933>) (Senior Lecturer, Medical Statistics), **Mike Marber** (<https://orcid.org/0000-0002-3463-7128>) (Professor of Cardiology), **Lucilla Poston** (<https://orcid.org/0000-0003-1100-2821>) (Professor of Maternal and Fetal Health), **Andrew Shennan** (<https://orcid.org/0000-0001-5273-3132>) (Professor of Obstetrics), **Paul Leeson** (<https://orcid.org/0000-0001-9181-9297>) (Professor of Cardiology), **Basky Thilaganathan** (<https://orcid.org/0000-0002-5531-4301>) (Professor of Fetal Medicine) and **Lucy C Chappell** (<https://orcid.org/0000-0001-6219-3379>) (Professor of Obstetrics) were involved in the study conception and in securing funding for the study.

**Anna Brockbank** (<https://orcid.org/0000-0002-2764-0556>) (Research Assistant, Obstetrics and Gynaecology) and **Carolyn Gill** (<https://orcid.org/0000-0003-0012-5105>) (Laboratory Manager, Obstetrics and Gynaecology) contributed to sample management and aspects of laboratory analysis.

**Alice Cox** (<https://orcid.org/0000-0001-5961-4793>) (Research Midwife, Obstetrics), **Jenie Sparkes** (<https://orcid.org/0000-0002-9973-544X>) (Research Midwife, Obstetrics) and **Anna Placzek** (<https://orcid.org/0000-0002-6745-5996>) (Trial Manager, Obstetrics) contributed to study management.

**Marcus Green** (<https://orcid.org/0000-0002-4561-8256>) (CEO Action on Pre-eclampsia, Pre-eclampsia) contributed through patient and public involvement throughout the study.

**Fergus McCarthy** and **Lucy C Chappell** were Co-Chief Investigators responsible for all aspects of the study.

**Jamie O'Driscoll** analysed all echocardiography assessments, supervised by **Paul Leeson**.

**Fergus McCarthy** and **Paul Seed** carried out statistical analyses.

**Fergus McCarthy** wrote the first draft of the report.

All authors reviewed, contributed to and approved the final version of the manuscript.

## Publication

McCarthy FP, O'Driscoll JM, Seed PT, Placzek A, Gill C, Sparkes J, *et al*. Multicenter cohort study, with a nested randomized comparison, to examine the cardiovascular impact of preterm preeclampsia [published online ahead of print August 30 2021]. *Hypertension* 2021.



## Data-sharing statement

All data requests should be submitted to the corresponding authors for consideration. Access to anonymised data may be granted following review.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.

## References

1. Townsend N, Williams J, Bhatnagar P, Wickramasinghe K, Rayner M. *Cardiovascular Disease Statistics, 2014*. London: British Heart Foundation; 2014.
2. Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas JP, Chappell L. Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records: a CALIBER study. *Circulation* 2019;**140**:1050–60. <https://doi.org/10.1161/CIRCULATIONAHA.118.038080>
3. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ* 2007;**335**:974. <https://doi.org/10.1136/bmj.39335.385301.BE>
4. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, *et al*. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. *J Am Coll Cardiol* 2011;**57**:1404–23. <https://doi.org/10.1016/j.jacc.2011.02.005>
5. British Heart Foundation. *Coronary Heart Disease Statistics in England, 2012*. URL: [www.bhf.org.uk/publications/view-publication.aspx?ps=1001546](http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001546) (accessed 15 June 2020).
6. Chappell LC, Brocklehurst P, Green ME, Hunter R, Hardy P, Juszczak E, *et al*. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. *Lancet* 2019;**394**:1181–90. [https://doi.org/10.1016/S0140-6736\(19\)31963-4](https://doi.org/10.1016/S0140-6736(19)31963-4)
7. Staff AC. Long-term cardiovascular health after stopping pre-eclampsia. *Lancet* 2019;**394**:1120–1. [https://doi.org/10.1016/S0140-6736\(19\)31993-2](https://doi.org/10.1016/S0140-6736(19)31993-2)
8. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, *et al*. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. *Pregnancy Hypertens* 2014;**4**:97–104. <https://doi.org/10.1016/j.preghy.2014.02.001>
9. National Institute for Health and Care Excellence. *Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy*. London: National Institute for Health and Care Excellence; 2010.
10. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, *et al*. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *J Am Soc Echocardiogr* 2009;**22**:107–33. <https://doi.org/10.1016/j.echo.2008.11.023>
11. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, *et al*. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016;**29**:277–314. <https://doi.org/10.1016/j.echo.2016.01.011>
12. Bijns BH, Cikes M, Claus P, Sutherland GR. Velocity and deformation imaging for the assessment of myocardial dysfunction. *Eur J Echocardiogr* 2009;**10**:216–26. <https://doi.org/10.1093/ejechocard/jen323>
13. Mogelvang R, Goetze JP, Pedersen SA, Olsen NT, Marott JL, Schnohr P, *et al*. Preclinical systolic and diastolic dysfunction assessed by tissue Doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. *J Card Fail* 2009;**15**:489–95. <https://doi.org/10.1016/j.cardfail.2009.01.005>

## REFERENCES

14. Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, *et al.* Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. *Circulation* 2009;**119**:2679–85. <https://doi.org/10.1161/CIRCULATIONAHA.108.793471>
15. Citro R, Bossone E, Kuersten B, Gregorio G, Salustri A. Tissue Doppler and strain imaging: anything left in the echo-lab? *Cardiovascular Ultrasound* 2008;**6**:54. <https://doi.org/10.1186/1476-7120-6-54>
16. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Côté AM, *et al.* Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. *Lancet* 2011;**377**:219–27. [https://doi.org/10.1016/S0140-6736\(10\)61351-7](https://doi.org/10.1016/S0140-6736(10)61351-7)
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, *et al.* Recommendations for chamber quantification. *Eur J Echocardiogr* 2006;**7**:79–108. <https://doi.org/10.1016/j.euje.2005.12.014>
18. Oxborough D, Batterham AM, Shave R, Artis N, Birch KM, Whyte G, *et al.* Interpretation of two-dimensional and tissue Doppler-derived strain (epsilon) and strain rate data: is there a need to normalize for individual variability in left ventricular morphology? *Eur J Echocardiogr* 2009;**10**:677–82. <https://doi.org/10.1093/ejechocard/jep037>
19. Batterham A, Shave R, Oxborough D, Whyte G, George K. Longitudinal plane colour tissue-Doppler myocardial velocities and their association with left ventricular length, volume, and mass in humans. *Eur J Echocardiogr* 2008;**9**:542–6. <https://doi.org/10.1093/ejechocard/jen114>
20. Dewey FE, Rosenthal D, Murphy DJ, Froelicher VF, Ashley EA. Does size matter? Clinical applications of scaling cardiac size and function for body size. *Circulation* 2008;**117**:2279–87. <https://doi.org/10.1161/CIRCULATIONAHA.107.736785>
21. Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. *Circulation* 1989;**79**:580–9. <https://doi.org/10.1161/01.cir.79.3.580>
22. Nagueh SF. Echocardiographic assessment of left ventricular relaxation and cardiac filling pressures. *Curr Heart Fail Rep* 2009;**6**:154–9. <https://doi.org/10.1007/s11897-009-0022-8>
23. Poppas A, Shroff SG, Korcarz CE, Hibbard JU, Berger DS, Lindheimer MD, Lang RM. Serial assessment of the cardiovascular system in normal pregnancy. Role of arterial compliance and pulsatile arterial load. *Circulation* 1997;**95**:2407–15. <https://doi.org/10.1161/01.cir.95.10.2407>
24. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. *Hypertension* 2011;**57**:85–93. <https://doi.org/10.1161/HYPERTENSIONAHA.110.162321>
25. Marciniak M, Bijmens B, Baltabaeva A, Marciniak A, Parsai C, Claus P, Sutherland GR. Interventricular interaction as a possible mechanism for the presence of a biphasic systolic velocity profile in normal left ventricular free walls. *Heart* 2008;**94**:1058–64. <https://doi.org/10.1136/hrt.2007.126938>
26. Baltabaeva A, Marciniak M, Bijmens B, *et al.* Regional left ventricular deformation and geometry analysis provides insights in myocardial remodelling in mild to moderate hypertension. *Eur J Echocardiogr* 2008;**9**:501–8. <https://doi.org/10.1016/j.euje.2007.08.004>
27. Marciniak A, Claus P, Sutherland GR, Marciniak M, Karu T, Baltabaeva A, *et al.* Changes in systolic left ventricular function in isolated mitral regurgitation. A strain rate imaging study. *Eur Heart J* 2007;**28**:2627–36. <https://doi.org/10.1093/eurheartj/ehm072>

28. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, *et al.* Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. *Eur J Echocardiogr* 2011;**12**:167–205. <https://doi.org/10.1093/ejechocard/jer021>
29. Kuznetsova T, Herbots L, Richart T, D'hooge J, Thijs L, Fagard RH, *et al.* Left ventricular strain and strain rate in a general population. *Eur Heart J* 2008;**29**:2014–23. <https://doi.org/10.1093/eurheartj/ehn280>
30. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, *et al.* The hypertensive disorders of pregnancy: ISSHP classification, diagnosis: management recommendations for international practice. *Pregnancy Hypertens* 2018;**13**:291–310. <https://doi.org/10.1016/j.preghy.2018.05.004>
31. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. *Am J Obst Gynecol* 2000;**183**:S1–22. <https://doi.org/10.1067/mob.2000.107928>
32. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, *et al.* Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. *BJOG* 2011;**118**(Suppl. 1):1–203. <https://doi.org/10.1111/j.1471-0528.2010.02847.x>
33. McQueen MJ, Kavsak PA, Xu L, Shestakovska O, Yusuf S. Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. *Clin Biochem* 2013;**46**:5–9. <https://doi.org/10.1016/j.clinbiochem.2012.10.003>
34. Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, *et al.* High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. *Lancet* 2018;**392**:919–28. [https://doi.org/10.1016/S0140-6736\(18\)31923-8](https://doi.org/10.1016/S0140-6736(18)31923-8)
35. Melchiorre K, Sutherland GR, Watt-Coote I, Liberati M, Thilaganathan B. Severe myocardial impairment and chamber dysfunction in preterm preeclampsia. *Hypertens Pregnancy* 2012;**31**:454–71. <https://doi.org/10.3109/10641955.2012.697951>
36. Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. *Hypertension* 2011;**58**:709–15. <https://doi.org/10.1161/HYPERTENSIONAHA.111.176537>
37. Villar J, Papageorgiou AT, Pang R, Ohuma EO, Cheikh Ismail L, Barros FC, *et al.* The likeness of fetal growth and newborn size across non-isolated populations in the INTERGROWTH-21st Project: the Fetal Growth Longitudinal Study and Newborn Cross-Sectional Study. *Lancet Diabetes Endocrinol* 2014;**2**:781–92. [https://doi.org/10.1016/S2213-8587\(14\)70121-4](https://doi.org/10.1016/S2213-8587(14)70121-4)
38. Castleman JS, Ganapathy R, Taki F, Lip GY, Steeds RP, Kotecha D. Echocardiographic structure and function in hypertensive disorders of pregnancy: a systematic review. *Circ Cardiovasc Imaging* 2016;**9**:e004888. <https://doi.org/10.1161/CIRCIMAGING.116.004888>
39. Vaught AJ, Kovell LC, Szymanski LM, Mayer SA, Seifert SM, Vaidya D, *et al.* Acute cardiac effects of severe pre-eclampsia. *J Am Coll Cardiol* 2018;**72**:1–11. <https://doi.org/10.1016/j.jacc.2018.04.048>
40. Melchiorre K, Sharma R, Thilaganathan B. Cardiovascular implications in preeclampsia: an overview. *Circulation* 2014;**130**:703–14. <https://doi.org/10.1161/CIRCULATIONAHA.113.003664>

41. Bokslag A, Franssen C, Alma LJ, Kovacevic I, Kesteren FV, Teunissen PW, *et al.* Early-onset preeclampsia predisposes to preclinical diastolic left ventricular dysfunction in the fifth decade of life: An observational study. *PLOS ONE* 2018;**13**:e0198908. <https://doi.org/10.1371/journal.pone.0198908>
42. Valensise H, Lo Presti D, Gagliardi G, Tiralongo GM, Pisani I, Novelli GP, Vasapollo B. Persistent maternal cardiac dysfunction after preeclampsia identifies patients at risk for recurrent preeclampsia. *Hypertension* 2016;**67**:748–53. <https://doi.org/10.1161/HYPERTENSIONAHA.115.06674>
43. Haas DM, Ehrental DB, Koch MA, Catov JM, Barnes SE, Facco F, *et al.* Pregnancy as a window to future cardiovascular health: design and implementation of the nuMoM2b Heart Health Study. *Am J Epidemiol* 2016;**183**:519–30. <https://doi.org/10.1093/aje/kwv309>
44. Hwang JW, Park SJ, Oh SY, Chang SA, Lee SC, Park SW, Kim DK. The risk factors that predict chronic hypertension after delivery in women with a history of hypertensive disorders of pregnancy. *Medicine* 2015;**94**:e1747. <https://doi.org/10.1097/MD.0000000000001747>
45. Ghossein-Doha C, Spaanderman M, van Kuijk SM, Kroon AA, Delhaas T, Peeters L. Long-term risk to develop hypertension in women with former preeclampsia: a longitudinal pilot study. *Reprod Sci* 2014;**21**:846–53. <https://doi.org/10.1177/1933719113518989>
46. Garovic VD, August P. Preeclampsia and the future risk of hypertension: the pregnant evidence. *Curr Hypertens Rep* 2013;**15**:114–21. <https://doi.org/10.1007/s11906-013-0329-4>
47. Estensen ME, Remme EW, Grindheim G, Smiseth OA, Segers P, Henriksen T, Aakhus S. Increased arterial stiffness in pre-eclamptic pregnancy at term and early and late postpartum: a combined echocardiographic and tonometric study. *Am J Hypertens* 2013;**26**:549–56. <https://doi.org/10.1093/ajh/hps067>
48. Levine LD, Lewey J, Koelper N, Downes KL, Arany Z, Elovitz MA, *et al.* Persistent cardiac dysfunction on echocardiography in African American women with severe preeclampsia. *Pregnancy Hypertens* 2019;**17**:127–32. <https://doi.org/10.1016/j.preghy.2019.05.021>
49. Breetveld NM, Ghossein-Doha C, van Kuijk SM, *et al.* Prevalence of asymptomatic heart failure in formerly pre-eclamptic women: a cohort study. *Ultrasound Obstet Gynecol* 2017;**49**:134–42. <https://doi.org/10.1002/uog.16014>
50. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, *et al.* Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. *BMJ* 2017;**358**:j3078. <https://doi.org/10.1136/bmj.j3078>
51. Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. *PLOS ONE* 2014;**9**:e91198. <https://doi.org/10.1371/journal.pone.0091198>
52. Wilmot KA, O'Flaherty M, Capewell S, Ford ES, Vaccarino V. Coronary heart disease mortality declines in the united states from 1979 through 2011: evidence for stagnation in young adults, especially women. *Circulation* 2015;**132**:997–1002. <https://doi.org/10.1161/CIRCULATIONAHA.115.015293>
53. Department of Economic and Social Affairs, United Nations. *Transforming Our World: The 2030 Agenda for Sustainable Development*. URL: <https://sdgs.un.org/2030agenda> (accessed April 2021).
54. Skjaerven R, Wilcox AJ, Klungsoyr K, Irgens LM, Vikse BE, Vatten LJ, Lie RT. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. *BMJ* 2012;**345**:e7677. <https://doi.org/10.1136/bmj.e7677>

55. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. *Lancet* 2001;**357**:2002–6. [https://doi.org/10.1016/S0140-6736\(00\)05112-6](https://doi.org/10.1016/S0140-6736(00)05112-6)
56. Board JBS. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). *Heart* 2014;**100**(Suppl. 2):ii1–67. <https://doi.org/10.1136/heartjnl-2014-305693>







**EME**  
**HS&DR**  
**HTA**  
**PGfAR**  
**PHR**

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care*

***Published by the NIHR Journals Library***